查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1239534

尿路感染 (UTI) 檢測市場：按傳染病類型、檢測類型、最終用戶、檢測試劑盒分類：2021-2031 年全球機會分析和行業預測

Urinary Tract Infection Testing Market By Infection Type, By Test Type, By End User, By Test Kit : Global Opportunity Analysis and Industry Forecast, 2021-2031
出版日期: | 出版商: Allied Market Research | 英文 280 Pages | 商品交期: 2-3個工作天內

價格

到 2031 年，全球尿路感染 (UTI) 檢測市場將達到 10.274 億美元，從 2021 年的 5.74 億美元預計到 2022 年至 2031 年的複合年增長率為 6.2% 。

腎髒病和糖尿病等慢性病的患病率上升，臨床醫生越來越傾向於進行完整的尿液分析，對疾病早期檢測的需求激增，醫院獲得性尿路感染 (UTI) 病例增加，尿液分析的使用越來越多測試是推動尿液分析測試市場增長的主要因素。 此外，對微創尿液診斷方法的需求不斷增加，先進的尿液分析測試方法的採用越來越多，以及旨在引入新的準確的尿路感染 (UTI) 診斷測試的研發活動增加是支持尿路感染 (UTI) 增長的一個因素測試市場。

由於與使用尿路感染 (UTI) 藥物相關的副作用，預計全球尿路感染 (UTI) 檢測市場將面臨市場發展挑戰。 尿路感染 (UTI) 檢測診斷和管理中的頻繁錯誤可能會阻礙預測期內的市場擴張。 缺乏與 UTI 相關的症狀識別、缺乏標準診斷標準和高樣本污染是市場擴張的主要障礙。

尿路感染 (UTI) 是女性、孕婦和圍絕經期婦女的常見病症。 尿路感染 (UTI) 與顯著的發病率和死亡率相關，並影響受影響個體的生活質量。 抗生素治療是一種成功的治療方法，可以縮短症狀的持續時間。 耐藥菌的出現、抗生素的不良作用和其他相關問題已經建立了一個研究框架，用於發現治療尿路結石的替代方法。

自然療法被廣泛用於治療許多疾病，以緩解症狀並改善整體健康狀況。 最近，草藥已被用於治療和預防許多疾病。 使用草藥的補充療法似乎是一個值得特別考慮的研究課題。 草藥療法已被證明可用於治療某些類型的尿路結石。

非抗生素治療是降低尿石症發病率並減輕其症狀的良好策略。 天然成分、礦物質和益生菌是為數不多的受到關注的藥物。 因為這些藥劑中的每一種都通過不同的機制起作用，所以以單一劑量聯合配製藥劑可以產生天然製劑，其可用於管理尿路結石增加的預防和治療方法。

COVID-19 大流行帶來了一些不確定性，導致世界各地的各種企業停滯不前，導致嚴重的經濟損失。 COVID-19疫情對製造業、供應鍊和物流行業產生了負面影響，也對醫療保健業務產生了負面影響。 由於 COVID-19，政府和醫療保健提供者正面臨前所未有的挑戰，影響監管環境和程序。 據報導，一名因 COVID-19 住院的患者被診斷出患有尿路感染 (UTI)。 然而，多項檢測發現，COVID-19 患者並沒有嚴重的泌尿系統症狀。 由於循環反應蛋白和降鈣素原等細菌感染的炎症標誌物升高，COVID-19 患者經常使用抗生素。 然而，這些人中的大多數都有經微生物學證實的細菌合併感染症狀。

內容

第 1 章介紹

第 2 章執行摘要

第 3 章市場概述

  • 市場定義和範圍
  • 主要發現
    • 主要影響因素
    • 主要投資領域
  • 波特的五力分析
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會
  • 分析 COVID-19 對市場的影響
  • 主要監管分析
  • 市場份額分析
  • 專利情況
  • 監管準則
  • 價值鏈分析

第 4 章尿路感染 (UTI) 檢測市場：按傳染病類型分類

  • 概覽
    • 市場規模和預測
  • 尿道炎
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 膀胱炎
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 腎盂腎炎
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 5 章尿路感染 (UTI) 檢測市場：按檢測類型

  • 概覽
    • 市場規模和預測
  • 尿檢
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 尿培養
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 敏感性測試
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 6 章尿路感染 (UTI) 檢測市場：按最終用戶分類

  • 概覽
    • 市場規模和預測
  • 醫院
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 診斷實驗室
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 研究所
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 7 章尿路感染 (UTI) 檢測市場：按檢測試劑盒分類

  • 概覽
    • 市場規模和預測
  • 家庭測試套件
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類
  • 測試套件
    • 主要市場趨勢、增長動力和機遇
    • 市場規模和預測：按地區
    • 市場份額分析：按國家/地區分類

第 8 章尿路感染 (UTI) 檢測市場：按地區

  • 概覽
    • 市場規模和預測：按地區
  • 北美
    • 主要趨勢和機會
    • 按傳染病類型劃分的市場規模和預測
    • 市場規模和按測試類型預測
    • 最終用戶的市場規模和預測
    • 市場規模和預測：按測試套件
    • 市場規模和預測：按國家/地區分類
      • 美國
      • 主要市場趨勢、增長動力和機遇
      • 按傳染病類型劃分的市場規模和預測
      • 市場規模和按測試類型預測
      • 最終用戶的市場規模和預測
      • 市場規模和預測：按測試套件
      • 加拿大
      • 主要市場趨勢、增長動力和機遇
      • 按傳染病類型劃分的市場規模和預測
      • 市場規模和按測試類型預測
      • 最終用戶的市場規模和預測
      • 市場規模和預測：按測試套件
      • 墨西哥
      • 主要市場趨勢、增長動力和機遇
      • 按傳染病類型劃分的市場規模和預測
      • 市場規模和按測試類型預測
      • 最終用戶的市場規模和預測
      • 市場規模和預測：按測試套件
  • 歐洲
    • 主要趨勢和機會
    • 按傳染病類型劃分的市場規模和預測
    • 市場規模和按測試類型預測
    • 最終用戶的市場規模和預測
    • 市場規模和預測：按測試套件
    • 市場規模和預測：按國家/地區分類
      • 德國
      • 主要市場趨勢、增長動力和機遇
      • 按傳染病類型劃分的市場規模和預測
      • 市場規模和按測試類型預測
      • 最終用戶的市場規模和預測
      • 市場規模和預測：按測試套件
      • 英國
      • 主要市場趨勢、增長動力和機遇
      • 按傳染病類型劃分的市場規模和預測
      • 市場規模和按測試類型預測
      • 最終用戶的市場規模和預測
      • 市場規模和預測：按測試套件
      • 法國
      • 主要市場趨勢、增長動力和機遇
      • 按傳染病類型劃分的市場規模和預測
      • 市場規模和按測試類型預測
      • 最終用戶的市場規模和預測
      • 市場規模和預測：按測試套件
      • 西班牙
      • 主要市場趨勢、增長動力和機遇
      • 按傳染病類型劃分的市場規模和預測
      • 市場規模和按測試類型預測
      • 最終用戶的市場規模和預測
      • 市場規模和預測：按測試套件
      • 意大利
      • 主要市場趨勢、增長動力和機遇
      • 按傳染病類型劃分的市場規模和預測
      • 市場規模和按測試類型預測
      • 最終用戶的市場規模和預測
      • 市場規模和預測：按測試套件
      • 其他歐洲
      • 主要市場趨勢、增長動力和機遇
      • 按傳染病類型劃分的市場規模和預測
      • 市場規模和按測試類型預測
      • 最終用戶的市場規模和預測
      • 市場規模和預測：按測試套件
  • 亞太地區
    • 主要趨勢和機會
    • 按傳染病類型劃分的市場規模和預測
    • 市場規模和按測試類型預測
    • 最終用戶的市場規模和預測
    • 市場規模和預測：按測試套件
    • 市場規模和預測：按國家/地區分類
      • 中國
      • 主要市場趨勢、增長動力和機遇
      • 按傳染病類型劃分的市場規模和預測
      • 市場規模和按測試類型預測
      • 最終用戶的市場規模和預測
      • 市場規模和預測：按測試套件
      • 日本
      • 主要市場趨勢、增長動力和機遇
      • 按傳染病類型劃分的市場規模和預測
      • 市場規模和按測試類型預測
      • 最終用戶的市場規模和預測
      • 市場規模和預測：按測試套件
      • 印度
      • 主要市場趨勢、增長動力和機遇
      • 按傳染病類型劃分的市場規模和預測
      • 市場規模和按測試類型預測
      • 最終用戶的市場規模和預測
      • 市場規模和預測：按測試套件
      • 韓國
      • 主要市場趨勢、增長動力和機遇
      • 按傳染病類型劃分的市場規模和預測
      • 市場規模和按測試類型預測
      • 最終用戶的市場規模和預測
      • 市場規模和預測：按測試套件
      • 澳大利亞
      • 主要市場趨勢、增長動力和機遇
      • 按傳染病類型劃分的市場規模和預測
      • 市場規模和按測試類型預測
      • 最終用戶的市場規模和預測
      • 市場規模和預測：按測試套件
      • 其他亞太地區
      • 主要市場趨勢、增長動力和機遇
      • 按傳染病類型劃分的市場規模和預測
      • 市場規模和按測試類型預測
      • 最終用戶的市場規模和預測
      • 市場規模和預測：按測試套件
  • 拉丁美洲/中東/非洲
    • 主要趨勢和機會
    • 按傳染病類型劃分的市場規模和預測
    • 市場規模和按測試類型預測
    • 最終用戶的市場規模和預測
    • 市場規模和預測：按測試套件
    • 市場規模和預測：按國家/地區分類
      • 巴西
      • 主要市場趨勢、增長動力和機遇
      • 按傳染病類型劃分的市場規模和預測
      • 市場規模和按測試類型預測
      • 最終用戶的市場規模和預測
      • 市場規模和預測：按測試套件
      • 沙特阿拉伯
      • 主要市場趨勢、增長動力和機遇
      • 按傳染病類型劃分的市場規模和預測
      • 市場規模和按測試類型預測
      • 最終用戶的市場規模和預測
      • 市場規模和預測：按測試套件
      • 阿拉伯聯合酋長國
      • 主要市場趨勢、增長動力和機遇
      • 按傳染病類型劃分的市場規模和預測
      • 市場規模和按測試類型預測
      • 最終用戶的市場規模和預測
      • 市場規模和預測：按測試套件
      • 南非
      • 主要市場趨勢、增長動力和機遇
      • 按傳染病類型劃分的市場規模和預測
      • 市場規模和按測試類型預測
      • 最終用戶的市場規模和預測
      • 市場規模和預測：按測試套件
      • 其他拉丁美洲/中東/非洲
      • 主要市場趨勢、增長動力和機遇
      • 按傳染病類型劃分的市場規模和預測
      • 市場規模和按測試類型預測
      • 最終用戶的市場規模和預測
      • 市場規模和預測：按測試套件

第 9 章競爭格局

  • 介紹
  • 關鍵成功策略
  • 排名前 10 位的玩家產品映射
  • 比賽儀表板
  • 競爭熱圖
  • 2021 年最佳球員排名

第 10 章公司簡介

  • Abbott Laboratories
  • Roche AG
  • Thermo Fisher Scientific, Inc.
  • Bio-Rad Laboratories
  • Danaher Corporation
  • ACON Laboratories Inc.
  • Cardinal Health Inc.
  • Stryker Corporation
  • SYSMEX CORPORATION
  • LabCorp（Laboratory Corporation of America Holdings）.
Product Code: A31362

The global urinary tract infection testing market is anticipated to reach $1,027.4 million by 2031, increasing from $574 million in 2021 at a CAGR of 6.2% from 2022 to 2031.

The rise in the prevalence of chronic diseases such as kidney disease and diabetes, an increase in the preference of clinicians for complete urine analysis, the surge in demand for early disease detection, a rise in cases of hospital-acquired urinary tract infection, and an increase in the use of urine analysis tests are the key factors driving the growth of the urinalysis test market. In addition, the rise in demand for minimally invasive urine diagnostic procedures, the increase in adoption of advanced urine analysis testing procedures, and the surge in R&D activities for the introduction of novel and accurate diagnostic tests are some factors that support the growth of the UTI testing market.

The global market for urinary tract infection testing is anticipated to experience development challenges due to side effects associated with the usage of UTI medications. Frequent errors in the diagnosis and management of urinary tract infection testing can impede market expansion during the forecast period. The lack of identifiable symptoms associated with UTI, the absence of standard diagnostic criteria, and the high contamination of samples are some of the key hurdles to market expansion.

Urinary tract infection (UTI) is a common occurrence in females, during pregnancy, and in peri- and postmenopausal women. UTIs are associated with severe morbidity and death, and they impact the quality of life of the affected people. Antibiotic therapy is a successful treatment that shortens the duration of symptoms. The development of resistance, the undesirable effects of antibiotics, and other linked issues lead to the establishment of a research framework to discover alternate means to managing UTIs.

Natural techniques are widely employed in the treatment of numerous ailments to alleviate symptoms and improve overall health.The use of medicinal herbs in the treatment and prevention of numerous diseases has expanded recently]. Complimentary therapy with medicinal herbs is a study topic that may merit special consideration. It has been demonstrated that herbal remedies can be useful in the management of a certain form of UTI.

Treatment with non-antibiotic drugs is a good strategy to lower the chance of developing UTI and to decrease its symptoms. Natural elements, minerals, and probiotics are among several agents that draw interest. Co-formulation of medications in a single dose form can create a natural formulation that is useful for both preventive and therapeutic methods in the management of UTI because each of these medications operates through a separate mechanism.

The COVID-19 pandemic brought several uncertainties, leading to severe economic losses as various businesses across the world were at a standstill. The arrival of the COVID-19 pandemic negatively impacted the manufacturing and supply chain & logistics industries, adversely affecting the healthcare business. Governments and healthcare providers are facing unheard-of issues owing to COVID-19, which has also had an impact on the regulatory environment and procedures. Patients with COVID-19 who were hospitalized were reportedly diagnosed with urinary tract infections. But multiple examinations have revealed that people with COVID-19 did not have severe urinary tract symptoms. Antibiotics are used extensively in COVID-19 patients due to high levels of blood inflammatory indicators of bacterial infection such as elevated C-reactive protein and procalcitonin. The majority of these individuals, however, had microbiologically verified bacterial co-infection symptoms.

The key players profiled in the report include F. Hoffmann-La Roche Ltd, Stryker, Abbott, Siemens, Sysmex Corporation, Cardinal Health, Danaher, Quidel, Bio-Rad Laboratories, Inc., and ACON Labs.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the urinary tract infection testing market analysis from 2021 to 2031 to identify the prevailing urinary tract infection testing market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the urinary tract infection testing market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global urinary tract infection testing market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Test Kit

  • Home Test Kits
  • Laboratory Test Kits

By Infection Type

  • Urethritis
  • Cystitis
  • Pyelonephritis

By Test Type

  • Urinalysis 
  • Urine Cultures
  • Susceptibility Testing

By End User

  • Hospitals
  • Diagnostic Laboratories
  • Research Institutes

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • United Arab Emirates
    • South Africa
    • Rest of LAMEA

Key Market Players

  • Thermo Fisher Scientific, Inc.
  • Bio-Rad Laboratories
  • Danaher Corporation
  • ACON Laboratories Inc.
  • Cardinal Health Inc.
  • Stryker Corporation
  • SYSMEX CORPORATION
  • Abbott Laboratories
  • Roche AG
  • LabCorp(Laboratory Corporation of America Holdings).

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research Methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
  • 3.4. Market dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities
  • 3.5. COVID-19 Impact Analysis on the market
  • 3.6. Key Regulation Analysis
  • 3.7. Market Share Analysis
  • 3.8. Patent Landscape
  • 3.9. Regulatory Guidelines
  • 3.10. Value Chain Analysis

CHAPTER 4: URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Urethritis
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Cystitis
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Pyelonephritis
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Urinalysis 
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Urine Cultures
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Susceptibility Testing
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: URINARY TRACT INFECTION TESTING MARKET, BY END USER

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospitals
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Diagnostic Laboratories
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Research Institutes
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT

  • 7.1. Overview
    • 7.1.1. Market size and forecast
  • 7.2. Home Test Kits
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by region
    • 7.2.3. Market share analysis by country
  • 7.3. Laboratory Test Kits
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by region
    • 7.3.3. Market share analysis by country

CHAPTER 8: URINARY TRACT INFECTION TESTING MARKET, BY REGION

  • 8.1. Overview
    • 8.1.1. Market size and forecast By Region
  • 8.2. North America
    • 8.2.1. Key trends and opportunities
    • 8.2.2. Market size and forecast, by Infection Type
    • 8.2.3. Market size and forecast, by Test Type
    • 8.2.4. Market size and forecast, by End User
    • 8.2.5. Market size and forecast, by Test Kit
    • 8.2.6. Market size and forecast, by country
      • 8.2.6.1. U.S.
      • 8.2.6.1.1. Key market trends, growth factors and opportunities
      • 8.2.6.1.2. Market size and forecast, by Infection Type
      • 8.2.6.1.3. Market size and forecast, by Test Type
      • 8.2.6.1.4. Market size and forecast, by End User
      • 8.2.6.1.5. Market size and forecast, by Test Kit
      • 8.2.6.2. Canada
      • 8.2.6.2.1. Key market trends, growth factors and opportunities
      • 8.2.6.2.2. Market size and forecast, by Infection Type
      • 8.2.6.2.3. Market size and forecast, by Test Type
      • 8.2.6.2.4. Market size and forecast, by End User
      • 8.2.6.2.5. Market size and forecast, by Test Kit
      • 8.2.6.3. Mexico
      • 8.2.6.3.1. Key market trends, growth factors and opportunities
      • 8.2.6.3.2. Market size and forecast, by Infection Type
      • 8.2.6.3.3. Market size and forecast, by Test Type
      • 8.2.6.3.4. Market size and forecast, by End User
      • 8.2.6.3.5. Market size and forecast, by Test Kit
  • 8.3. Europe
    • 8.3.1. Key trends and opportunities
    • 8.3.2. Market size and forecast, by Infection Type
    • 8.3.3. Market size and forecast, by Test Type
    • 8.3.4. Market size and forecast, by End User
    • 8.3.5. Market size and forecast, by Test Kit
    • 8.3.6. Market size and forecast, by country
      • 8.3.6.1. Germany
      • 8.3.6.1.1. Key market trends, growth factors and opportunities
      • 8.3.6.1.2. Market size and forecast, by Infection Type
      • 8.3.6.1.3. Market size and forecast, by Test Type
      • 8.3.6.1.4. Market size and forecast, by End User
      • 8.3.6.1.5. Market size and forecast, by Test Kit
      • 8.3.6.2. UK
      • 8.3.6.2.1. Key market trends, growth factors and opportunities
      • 8.3.6.2.2. Market size and forecast, by Infection Type
      • 8.3.6.2.3. Market size and forecast, by Test Type
      • 8.3.6.2.4. Market size and forecast, by End User
      • 8.3.6.2.5. Market size and forecast, by Test Kit
      • 8.3.6.3. France
      • 8.3.6.3.1. Key market trends, growth factors and opportunities
      • 8.3.6.3.2. Market size and forecast, by Infection Type
      • 8.3.6.3.3. Market size and forecast, by Test Type
      • 8.3.6.3.4. Market size and forecast, by End User
      • 8.3.6.3.5. Market size and forecast, by Test Kit
      • 8.3.6.4. Spain
      • 8.3.6.4.1. Key market trends, growth factors and opportunities
      • 8.3.6.4.2. Market size and forecast, by Infection Type
      • 8.3.6.4.3. Market size and forecast, by Test Type
      • 8.3.6.4.4. Market size and forecast, by End User
      • 8.3.6.4.5. Market size and forecast, by Test Kit
      • 8.3.6.5. Italy
      • 8.3.6.5.1. Key market trends, growth factors and opportunities
      • 8.3.6.5.2. Market size and forecast, by Infection Type
      • 8.3.6.5.3. Market size and forecast, by Test Type
      • 8.3.6.5.4. Market size and forecast, by End User
      • 8.3.6.5.5. Market size and forecast, by Test Kit
      • 8.3.6.6. Rest of Europe
      • 8.3.6.6.1. Key market trends, growth factors and opportunities
      • 8.3.6.6.2. Market size and forecast, by Infection Type
      • 8.3.6.6.3. Market size and forecast, by Test Type
      • 8.3.6.6.4. Market size and forecast, by End User
      • 8.3.6.6.5. Market size and forecast, by Test Kit
  • 8.4. Asia-Pacific
    • 8.4.1. Key trends and opportunities
    • 8.4.2. Market size and forecast, by Infection Type
    • 8.4.3. Market size and forecast, by Test Type
    • 8.4.4. Market size and forecast, by End User
    • 8.4.5. Market size and forecast, by Test Kit
    • 8.4.6. Market size and forecast, by country
      • 8.4.6.1. China
      • 8.4.6.1.1. Key market trends, growth factors and opportunities
      • 8.4.6.1.2. Market size and forecast, by Infection Type
      • 8.4.6.1.3. Market size and forecast, by Test Type
      • 8.4.6.1.4. Market size and forecast, by End User
      • 8.4.6.1.5. Market size and forecast, by Test Kit
      • 8.4.6.2. Japan
      • 8.4.6.2.1. Key market trends, growth factors and opportunities
      • 8.4.6.2.2. Market size and forecast, by Infection Type
      • 8.4.6.2.3. Market size and forecast, by Test Type
      • 8.4.6.2.4. Market size and forecast, by End User
      • 8.4.6.2.5. Market size and forecast, by Test Kit
      • 8.4.6.3. India
      • 8.4.6.3.1. Key market trends, growth factors and opportunities
      • 8.4.6.3.2. Market size and forecast, by Infection Type
      • 8.4.6.3.3. Market size and forecast, by Test Type
      • 8.4.6.3.4. Market size and forecast, by End User
      • 8.4.6.3.5. Market size and forecast, by Test Kit
      • 8.4.6.4. South Korea
      • 8.4.6.4.1. Key market trends, growth factors and opportunities
      • 8.4.6.4.2. Market size and forecast, by Infection Type
      • 8.4.6.4.3. Market size and forecast, by Test Type
      • 8.4.6.4.4. Market size and forecast, by End User
      • 8.4.6.4.5. Market size and forecast, by Test Kit
      • 8.4.6.5. Australia
      • 8.4.6.5.1. Key market trends, growth factors and opportunities
      • 8.4.6.5.2. Market size and forecast, by Infection Type
      • 8.4.6.5.3. Market size and forecast, by Test Type
      • 8.4.6.5.4. Market size and forecast, by End User
      • 8.4.6.5.5. Market size and forecast, by Test Kit
      • 8.4.6.6. Rest of Asia-Pacific
      • 8.4.6.6.1. Key market trends, growth factors and opportunities
      • 8.4.6.6.2. Market size and forecast, by Infection Type
      • 8.4.6.6.3. Market size and forecast, by Test Type
      • 8.4.6.6.4. Market size and forecast, by End User
      • 8.4.6.6.5. Market size and forecast, by Test Kit
  • 8.5. LAMEA
    • 8.5.1. Key trends and opportunities
    • 8.5.2. Market size and forecast, by Infection Type
    • 8.5.3. Market size and forecast, by Test Type
    • 8.5.4. Market size and forecast, by End User
    • 8.5.5. Market size and forecast, by Test Kit
    • 8.5.6. Market size and forecast, by country
      • 8.5.6.1. Brazil
      • 8.5.6.1.1. Key market trends, growth factors and opportunities
      • 8.5.6.1.2. Market size and forecast, by Infection Type
      • 8.5.6.1.3. Market size and forecast, by Test Type
      • 8.5.6.1.4. Market size and forecast, by End User
      • 8.5.6.1.5. Market size and forecast, by Test Kit
      • 8.5.6.2. Saudi Arabia
      • 8.5.6.2.1. Key market trends, growth factors and opportunities
      • 8.5.6.2.2. Market size and forecast, by Infection Type
      • 8.5.6.2.3. Market size and forecast, by Test Type
      • 8.5.6.2.4. Market size and forecast, by End User
      • 8.5.6.2.5. Market size and forecast, by Test Kit
      • 8.5.6.3. United Arab Emirates
      • 8.5.6.3.1. Key market trends, growth factors and opportunities
      • 8.5.6.3.2. Market size and forecast, by Infection Type
      • 8.5.6.3.3. Market size and forecast, by Test Type
      • 8.5.6.3.4. Market size and forecast, by End User
      • 8.5.6.3.5. Market size and forecast, by Test Kit
      • 8.5.6.4. South Africa
      • 8.5.6.4.1. Key market trends, growth factors and opportunities
      • 8.5.6.4.2. Market size and forecast, by Infection Type
      • 8.5.6.4.3. Market size and forecast, by Test Type
      • 8.5.6.4.4. Market size and forecast, by End User
      • 8.5.6.4.5. Market size and forecast, by Test Kit
      • 8.5.6.5. Rest of LAMEA
      • 8.5.6.5.1. Key market trends, growth factors and opportunities
      • 8.5.6.5.2. Market size and forecast, by Infection Type
      • 8.5.6.5.3. Market size and forecast, by Test Type
      • 8.5.6.5.4. Market size and forecast, by End User
      • 8.5.6.5.5. Market size and forecast, by Test Kit

CHAPTER 9: COMPETITIVE LANDSCAPE

  • 9.1. Introduction
  • 9.2. Top winning strategies
  • 9.3. Product Mapping of Top 10 Player
  • 9.4. Competitive Dashboard
  • 9.5. Competitive Heatmap
  • 9.6. Top player positioning, 2021

CHAPTER 10: COMPANY PROFILES

  • 10.1. Abbott Laboratories
    • 10.1.1. Company overview
    • 10.1.2. Key Executives
    • 10.1.3. Company snapshot
  • 10.2. Roche AG
    • 10.2.1. Company overview
    • 10.2.2. Key Executives
    • 10.2.3. Company snapshot
  • 10.3. Thermo Fisher Scientific, Inc.
    • 10.3.1. Company overview
    • 10.3.2. Key Executives
    • 10.3.3. Company snapshot
  • 10.4. Bio-Rad Laboratories
    • 10.4.1. Company overview
    • 10.4.2. Key Executives
    • 10.4.3. Company snapshot
  • 10.5. Danaher Corporation
    • 10.5.1. Company overview
    • 10.5.2. Key Executives
    • 10.5.3. Company snapshot
  • 10.6. ACON Laboratories Inc.
    • 10.6.1. Company overview
    • 10.6.2. Key Executives
    • 10.6.3. Company snapshot
  • 10.7. Cardinal Health Inc.
    • 10.7.1. Company overview
    • 10.7.2. Key Executives
    • 10.7.3. Company snapshot
  • 10.8. Stryker Corporation
    • 10.8.1. Company overview
    • 10.8.2. Key Executives
    • 10.8.3. Company snapshot
  • 10.9. SYSMEX CORPORATION
    • 10.9.1. Company overview
    • 10.9.2. Key Executives
    • 10.9.3. Company snapshot
  • 10.10. LabCorp(Laboratory Corporation of America Holdings).
    • 10.10.1. Company overview
    • 10.10.2. Key Executives
    • 10.10.3. Company snapshot

LIST OF TABLES

  • TABLE 01. GLOBAL URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 02. URINARY TRACT INFECTION TESTING MARKET FOR URETHRITIS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 03. URINARY TRACT INFECTION TESTING MARKET FOR CYSTITIS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 04. URINARY TRACT INFECTION TESTING MARKET FOR PYELONEPHRITIS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 05. GLOBAL URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 06. URINARY TRACT INFECTION TESTING MARKET FOR URINALYSIS , BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 07. URINARY TRACT INFECTION TESTING MARKET FOR URINE CULTURES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 08. URINARY TRACT INFECTION TESTING MARKET FOR SUSCEPTIBILITY TESTING, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 09. GLOBAL URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 10. URINARY TRACT INFECTION TESTING MARKET FOR HOSPITALS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 11. URINARY TRACT INFECTION TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 12. URINARY TRACT INFECTION TESTING MARKET FOR RESEARCH INSTITUTES, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 13. GLOBAL URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 14. URINARY TRACT INFECTION TESTING MARKET FOR HOME TEST KITS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 15. URINARY TRACT INFECTION TESTING MARKET FOR LABORATORY TEST KITS, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 16. URINARY TRACT INFECTION TESTING MARKET, BY REGION, 2021-2031 (REVENUE, $MILLION)
  • TABLE 17. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 18. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 19. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 20. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 21. NORTH AMERICA URINARY TRACT INFECTION TESTING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 22. U.S. URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 23. U.S. URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 24. U.S. URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 25. U.S. URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 26. CANADA URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 27. CANADA URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 28. CANADA URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 29. CANADA URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 30. MEXICO URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 31. MEXICO URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 32. MEXICO URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 33. MEXICO URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 34. EUROPE URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 35. EUROPE URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 36. EUROPE URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 37. EUROPE URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 38. EUROPE URINARY TRACT INFECTION TESTING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 39. GERMANY URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 40. GERMANY URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 41. GERMANY URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 42. GERMANY URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 43. UK URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 44. UK URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 45. UK URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 46. UK URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 47. FRANCE URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 48. FRANCE URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 49. FRANCE URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 50. FRANCE URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 51. SPAIN URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 52. SPAIN URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 53. SPAIN URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 54. SPAIN URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 55. ITALY URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 56. ITALY URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 57. ITALY URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 58. ITALY URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 59. REST OF EUROPE URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 60. REST OF EUROPE URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 61. REST OF EUROPE URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 62. REST OF EUROPE URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 63. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 64. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 65. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 66. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 67. ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 68. CHINA URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 69. CHINA URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 70. CHINA URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 71. CHINA URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 72. JAPAN URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 73. JAPAN URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 74. JAPAN URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 75. JAPAN URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 76. INDIA URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 77. INDIA URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 78. INDIA URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 79. INDIA URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 80. SOUTH KOREA URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 81. SOUTH KOREA URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 82. SOUTH KOREA URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 83. SOUTH KOREA URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 84. AUSTRALIA URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 85. AUSTRALIA URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 86. AUSTRALIA URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 87. AUSTRALIA URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 88. REST OF ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 89. REST OF ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 90. REST OF ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 91. REST OF ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 92. LAMEA URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 93. LAMEA URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 94. LAMEA URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 95. LAMEA URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 96. LAMEA URINARY TRACT INFECTION TESTING MARKET, BY COUNTRY, 2021-2031 (REVENUE, $MILLION)
  • TABLE 97. BRAZIL URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 98. BRAZIL URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 99. BRAZIL URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 100. BRAZIL URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 101. SAUDI ARABIA URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 102. SAUDI ARABIA URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 103. SAUDI ARABIA URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 104. SAUDI ARABIA URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 105. UNITED ARAB EMIRATES URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 106. UNITED ARAB EMIRATES URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 107. UNITED ARAB EMIRATES URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 108. UNITED ARAB EMIRATES URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 109. SOUTH AFRICA URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 110. SOUTH AFRICA URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 111. SOUTH AFRICA URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 112. SOUTH AFRICA URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 113. REST OF LAMEA URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 114. REST OF LAMEA URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021-2031 (REVENUE, $MILLION)
  • TABLE 115. REST OF LAMEA URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021-2031 (REVENUE, $MILLION)
  • TABLE 116. REST OF LAMEA URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021-2031 (REVENUE, $MILLION)
  • TABLE 117. ABBOTT LABORATORIES: KEY EXECUTIVES
  • TABLE 118. ABBOTT LABORATORIES: COMPANY SNAPSHOT
  • TABLE 119. ROCHE AG: KEY EXECUTIVES
  • TABLE 120. ROCHE AG: COMPANY SNAPSHOT
  • TABLE 121. THERMO FISHER SCIENTIFIC, INC.: KEY EXECUTIVES
  • TABLE 122. THERMO FISHER SCIENTIFIC, INC.: COMPANY SNAPSHOT
  • TABLE 123. BIO-RAD LABORATORIES: KEY EXECUTIVES
  • TABLE 124. BIO-RAD LABORATORIES: COMPANY SNAPSHOT
  • TABLE 125. DANAHER CORPORATION: KEY EXECUTIVES
  • TABLE 126. DANAHER CORPORATION: COMPANY SNAPSHOT
  • TABLE 127. ACON LABORATORIES INC.: KEY EXECUTIVES
  • TABLE 128. ACON LABORATORIES INC.: COMPANY SNAPSHOT
  • TABLE 129. CARDINAL HEALTH INC.: KEY EXECUTIVES
  • TABLE 130. CARDINAL HEALTH INC.: COMPANY SNAPSHOT
  • TABLE 131. STRYKER CORPORATION: KEY EXECUTIVES
  • TABLE 132. STRYKER CORPORATION: COMPANY SNAPSHOT
  • TABLE 133. SYSMEX CORPORATION: KEY EXECUTIVES
  • TABLE 134. SYSMEX CORPORATION: COMPANY SNAPSHOT
  • TABLE 135. LABCORP(LABORATORY CORPORATION OF AMERICA HOLDINGS).: KEY EXECUTIVES
  • TABLE 136. LABCORP(LABORATORY CORPORATION OF AMERICA HOLDINGS).: COMPANY SNAPSHOT

LIST OF FIGURES

  • FIGURE 01. URINARY TRACT INFECTION TESTING MARKET, 2021-2031
  • FIGURE 02. SEGMENTATION OF URINARY TRACT INFECTION TESTING MARKET, 2021-2031
  • FIGURE 03. TOP INVESTMENT POCKETS IN URINARY TRACT INFECTION TESTING MARKET (2022-2031)
  • FIGURE 04. PORTER FIVE-1
  • FIGURE 05. PORTER FIVE-2
  • FIGURE 06. PORTER FIVE-3
  • FIGURE 07. PORTER FIVE-4
  • FIGURE 08. PORTER FIVE-5
  • FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALURINARY TRACT INFECTION TESTING MARKET
  • FIGURE 10. IMPACT OF KEY REGULATION: URINARY TRACT INFECTION TESTING MARKET
  • FIGURE 11. MARKET SHARE ANALYSIS: URINARY TRACT INFECTION TESTING MARKET
  • FIGURE 12. PATENT ANALYSIS BY COMPANY
  • FIGURE 13. PATENT ANALYSIS BY COUNTRY
  • FIGURE 14. REGULATORY GUIDELINES: URINARY TRACT INFECTION TESTING MARKET
  • FIGURE 15. VALUE CHAIN ANALYSIS: URINARY TRACT INFECTION TESTING MARKET
  • FIGURE 16. URINARY TRACT INFECTION TESTING MARKET, BY INFECTION TYPE, 2021(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF URINARY TRACT INFECTION TESTING MARKET FOR URETHRITIS, BY COUNTRY 2021-2031(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF URINARY TRACT INFECTION TESTING MARKET FOR CYSTITIS, BY COUNTRY 2021-2031(%)
  • FIGURE 19. COMPARATIVE SHARE ANALYSIS OF URINARY TRACT INFECTION TESTING MARKET FOR PYELONEPHRITIS, BY COUNTRY 2021-2031(%)
  • FIGURE 20. URINARY TRACT INFECTION TESTING MARKET, BY TEST TYPE, 2021(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF URINARY TRACT INFECTION TESTING MARKET FOR URINALYSIS , BY COUNTRY 2021-2031(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF URINARY TRACT INFECTION TESTING MARKET FOR URINE CULTURES, BY COUNTRY 2021-2031(%)
  • FIGURE 23. COMPARATIVE SHARE ANALYSIS OF URINARY TRACT INFECTION TESTING MARKET FOR SUSCEPTIBILITY TESTING, BY COUNTRY 2021-2031(%)
  • FIGURE 24. URINARY TRACT INFECTION TESTING MARKET, BY END USER, 2021(%)
  • FIGURE 25. COMPARATIVE SHARE ANALYSIS OF URINARY TRACT INFECTION TESTING MARKET FOR HOSPITALS, BY COUNTRY 2021-2031(%)
  • FIGURE 26. COMPARATIVE SHARE ANALYSIS OF URINARY TRACT INFECTION TESTING MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY 2021-2031(%)
  • FIGURE 27. COMPARATIVE SHARE ANALYSIS OF URINARY TRACT INFECTION TESTING MARKET FOR RESEARCH INSTITUTES, BY COUNTRY 2021-2031(%)
  • FIGURE 28. URINARY TRACT INFECTION TESTING MARKET, BY TEST KIT, 2021(%)
  • FIGURE 29. COMPARATIVE SHARE ANALYSIS OF URINARY TRACT INFECTION TESTING MARKET FOR HOME TEST KITS, BY COUNTRY 2021-2031(%)
  • FIGURE 30. COMPARATIVE SHARE ANALYSIS OF URINARY TRACT INFECTION TESTING MARKET FOR LABORATORY TEST KITS, BY COUNTRY 2021-2031(%)
  • FIGURE 31. URINARY TRACT INFECTION TESTING MARKET BY REGION, 2021
  • FIGURE 32. U.S. URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
  • FIGURE 33. CANADA URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
  • FIGURE 34. MEXICO URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
  • FIGURE 35. GERMANY URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
  • FIGURE 36. UK URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
  • FIGURE 37. FRANCE URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
  • FIGURE 38. SPAIN URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
  • FIGURE 39. ITALY URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
  • FIGURE 40. REST OF EUROPE URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
  • FIGURE 41. CHINA URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
  • FIGURE 42. JAPAN URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
  • FIGURE 43. INDIA URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
  • FIGURE 44. SOUTH KOREA URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
  • FIGURE 45. AUSTRALIA URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
  • FIGURE 46. REST OF ASIA-PACIFIC URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
  • FIGURE 47. BRAZIL URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
  • FIGURE 48. SAUDI ARABIA URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
  • FIGURE 49. UNITED ARAB EMIRATES URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
  • FIGURE 50. SOUTH AFRICA URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
  • FIGURE 51. REST OF LAMEA URINARY TRACT INFECTION TESTING MARKET, 2021-2031 ($MILLION)
  • FIGURE 52. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 53. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 54. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 55. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 56. COMPETITIVE DASHBOARD
  • FIGURE 57. COMPETITIVE HEATMAP: URINARY TRACT INFECTION TESTING MARKET
  • FIGURE 58. TOP PLAYER POSITIONING, 2021